Prevalence and Clinical Associations of Lupus Anticoagulant, Anticardiolipin Antibodies, and Anti-beta2-glycoprotein I Antibodies in Patients with Systemic Lupus Erythematosus
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background : The presence of antiphospholipid antibodies (aPLs) is associated with the clinical features of antiphospholipid syndrome (APS), which comprises venous and arterial thrombosis and pregnancy loss, and systemic lupus erythematosus (SLE). The prevalence of aPLs has been reported to be different in patient populations affected by either of these conditions. We performed a retrospective study to evaluate the prevalence and clinical associations of aPLs, including lupus anticoagulant (LAC), anticardiolipin (aCL), and anti-beta2-glycoprotein I antibodies (anti-beta2-GPI) in a cohort of Korean patients with SLE. Methods : This study included samples from 88 SLE patients for whom aPL testing had been advised between June 2006 and July 2009 at the Dong-A University Hospital. Serum and plasma samples were tested for LAC, aCL (IgG, IgM), and anti-beta2-GPI (IgG, IgM) antibodies. Clinical data from patients were obtained from a review of medical records. Results : LAC was the most common (34.1% of total patients, 30/88) antibody, followed by IgM aCL (31.8%, 28/88), IgG aCL (18.2%, 16/88), and IgM and IgG anti-beta2-GPI (both 5.7%, 5/88 each). Positivity for LAC was strongly associated with venous/arterial thrombosis (P=0.002). Conclusions : LAC was the most common antibody detected in Korean SLE patients and is shown to have a significant association with the presence of venous/arterial thrombosis. The measurement of LAC may be clinically useful in identifying patients with SLE who are at a high risk for venous/arterial thrombosis. (Korean J Lab Med 2010;30:38-44)
Abstract
Background : The presence of antiphospholipid antibodies (aPLs) is associated with the clinical features of antiphospholipid syndrome (APS), which comprises venous and arterial thrombosis and pregnancy loss, and systemic lupus erythematosus (SLE). The prevalence of aPLs has been reported to be different in patient populations affected by either of these conditions. We performed a retrospective study to evaluate the prevalence and clinical associations of aPLs, including lupus anticoagulant (LAC), anticardiolipin (aCL), and anti-beta2-glycoprotein I antibodies (anti-beta2-GPI) in a cohort of Korean patients with SLE. Methods : This study included samples from 88 SLE patients for whom aPL testing had been advised between June 2006 and July 2009 at the Dong-A University Hospital. Serum and plasma samples were tested for LAC, aCL (IgG, IgM), and anti-beta2-GPI (IgG, IgM) antibodies. Clinical data from patients were obtained from a review of medical records. Results : LAC was the most common (34.1% of total patients, 30/88) antibody, followed by IgM aCL (31.8%, 28/88), IgG aCL (18.2%, 16/88), and IgM and IgG anti-beta2-GPI (both 5.7%, 5/88 each). Positivity for LAC was strongly associated with venous/arterial thrombosis (P=0.002). Conclusions : LAC was the most common antibody detected in Korean SLE patients and is shown to have a significant association with the presence of venous/arterial thrombosis. The measurement of LAC may be clinically useful in identifying patients with SLE who are at a high risk for venous/arterial thrombosis. (Korean J Lab Med 2010;30:38-44)
참고문헌 (28)
- Sammaritano LR, "Antiphospholipid antibody syndrome: immunologic and clinical aspects", Semin Arthritis Rheum, 20, pp.81~96 (1990)
- Love PE, "Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance", Ann Intern Med, 112, pp.682~698 (1990)
- Uthman I, "The hematologic manifestations of the antiphospholipid syndrome", Blood Rev, 22, pp.187~194 (2008)
- Miyakis S, "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)", J Thromb Haemost, 4, pp.295~306 (2006)
- Galli M, "Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature", Blood, 101, pp.1827~1832 (2003)
- Galli M, "Antiphospholipid antibodies and pregnancy", Best Pract Res Clin Haematol, 16, pp.211~225 (2003)
- Somers E, "Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus", J Rheumatol, 29, pp.2531~2536 (2002)
- Tsutsumi A, "Antibodies to beta 2-glycoprotein and clinical manifestations in patients with systemic lupus erythematosus", Arthritis Rheum, 39, pp.1466~1474 (1996)
- Sahin M, "Antibodies to beta2-glycoprotein-I: relation of anticardiolipin antibodies with clinical and laboratory parameters in patients with systemic lupus erythematosus", Clin Biochem, 40, pp.526~530 (2007)
- Mok CC, "Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups", Arthritis Rheum, 52, pp.2774~2782 (2005)
- Lee SS, "Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus", J Rheumatol, 28, pp.520~524 (2001)
- Hochberg MC, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus", Arthritis Rheum, 40, pp.1725~ (1997)
- Ghirardello A, "Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?", Ann Rheum Dis, 53, pp.140~142 (1994)
- Petri M, "Epidemiology of the antiphospholipid antibody syndrome", J Autoimmun, 15, pp.145~151 (2000)
- Danowski A, "Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus", J Rheumatol, 33, pp.1775~1779 (2006)
- Mok MY, "Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus", J Rheumatol, 32, pp.622~628 (2005)
- Lee SG, "The association of HLA-DRB1 and DQB1 alleles and a study of anticardiolipin antibody and anti-beta2 glycoprotein I antibody in Korean SLE patients", Immune Netw, 2, pp.227~232 (2002)
- Swadz@ba J, "Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases", J Thromb Haemost, 5, pp.1883~1889 (2007)
- Phospholipid-dependent antibodies. Annual Report, "Lupus AntiCoagulant", pp.2002, Scientific and Standardization Committee
- Obermoser G, "Clinical significance of anticardiolipin and anti-b2-glycoprotein I antibodies", Int Arch Allergy Immunol, 135, pp.148~153 (2004)
- Nash MJ, "The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies", J Thromb Haemost, 2, pp.1077~1081 (2004)
- Martinez-Berriotxoa A, "Gabriel Erdozain J, Villar I, et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus", Lupus, 16, pp.810~816 (2007)
- Arvieux J, "Measurement of antiphospholipid antibodies by ELISA using b2-glycoprotein I as an antigen", J Immunol Methods, 143, pp.223~229 (1991)
- Lee EY, "Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis?", Thromb Res, 111, pp.29~32 (2003)
- Ebeling F, "Beta-2-glycoprotein I antibodies in patients with thrombosis", Scand J Clin Lab Invest, 63, pp.111~118 (2003)
- Stasi R, "Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura", Blood, 84, pp.4203~4208 (1994)
- Cervera R, "Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients", Arthritis Rheum, 46, pp.1019~1027 (2002)
- Kim TM, "Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea", Thromb Res, 123, pp.436~443 (2009)